Odanacatib for Postmenopausal Osteoporosis
Physician's Weekly,
Postmenopausal osteoporosis is a bone disease characterized by the loss of too much bone from the body after menopause.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
Overview of attention for article published in The Lancet Diabetes & Endocrinology, October 2019
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (97th percentile)
-
High Attention Score compared to outputs of the same age and source (84th percentile)
Readers on
- mendeley
- 196 Mendeley